Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New HIV strategy aims to help people who inject drugs in india

NCT ID NCT05165810

Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether starting HIV treatment on the same day and providing care in community centers for people who inject drugs improves viral suppression. 800 participants were randomly assigned to same-day or standard treatment start, and to community or government-based care. The goal was to see if these changes help more people stay on treatment and achieve undetectable virus levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Same-day ART initiation and community-based HIV care
What this could lead to
If successful, this approach could make HIV treatment more accessible and effective for people who inject drugs, leading to better viral suppression and reduced transmission.
What could go wrong
This is a completed trial, but results may not apply to all settings. The interventions are behavioral, so individual adherence and local resources can affect outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

800 people

The number who actually took part.

Started

Mar 2023

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

PHASE 1 Inclusion Criteria: * 18 years of age or older * Reports injection drug use in prior 24 months * Documented HIV positive * Antiretroviral therapy naïve * HIV RNA 1,000 c/mL or higher * If previously linked to HIV care, able and willing to provide govt. ART book for documentation of care received. PHASE 1 Exclusion Criteria: * Pregnant (if female) * Does not speak English, Hindi, or local language * Plans to migrate in next 12 months * Not competent to participate in the study or provide written informed consent. PHASE 2 Inclusion Criteria: • Participants who experience treatment failure at 6 months (HIV RNA\>1000c/mL) PHASE 2 Exclusion Criteria: • Participants who do not experience treatment failure at 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infections

Contacts and locations

Locations

  • POINTER study -YRGCARE

    New Delhi, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.